The drug, Wegovy, uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount ...
Obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three ...
Weight loss jabs like Ozempic can cut the risk of heart attacks or strokes by a fifth, a “game-changing” new study has found. The anti-obesity injections could reduce the risk in obese people ...
Marketed as Wegovy, Ozempic and Rybelsus, semaglutide injections may benefit obese patients even if they don't lose weight.
A weekly dose of Wegovy, alongside standard care for the prevention of heart attacks or stroke, lowered the risk by 20% ...
A groundbreaking study has revealed that an anti-obesity jab containing semaglutide, a drug used to treat obesity, significantly reduces the risk of heart attacks and strokes, regardless of the ...
Ozempic could dramatically reduce the risk of heart attacks and stroke, a new study indicates. The weight loss jab has become ...
An anti-obesity drug could have additional health benefits including reducing the risk of heart attacks and strokes a new study has revealed. A five-year study was carried out by a team led by ...